New York City-based Pfizer awarded UC Riverside associate professor Declan McCole, MD, a two-year, $150,000 grant to support his inflammatory bowel disease research.
Here's what you should know.
1. Dr. McCole is leading research exploring therapeutic targets for correcting intestinal barrier defects in IBD patients who have T-cell protein tyrosine phosphatase mutations.
2. Dr. McCole said although TCPTP mutations increase IBD risk, there are no therapeutic strategies aimed at correcting the mutations' consequences.
3. Dr. McCole is using a molecular biology approach to interrupt the JAK-STAT signaling pathway and claims disruption may correct barrier defects related to TCPTP activity loss.
4. Dr. McCole concluded, "We expect our findings from this research project will ultimately improve diagnostic and treatment options for patients with IBD."
More articles on gastroenterology:
The top 45 'A' rated Angie's List gastroenterology practices across the US
6 facts on gastroenterologist salary in 2017
Scientists on brink of identifying irritable bowel syndrome's cause: 4 study insights